Claims for Patent: 9,688,961

Summary for Patent: 9,688,961

Title:	Process of preparing human multipotent stem cells co-expressing CD34 and CD73
Abstract:	The present invention relates to testis somatic cell-derived pluripotent stem cells, and more particularly, to pluripotent adult stem cells which exhibit a positive immune reaction to both CD34 and CD73 and which are derived from testis somatic cells. The present invention further relates to a method for producing the testis somatic cell-derived pluripotent stem cells, and to a pharmaceutical composition including same for the treatment of erectile dysfunction.
Inventor(s):	Lee; Dong-Ryul (Seoul, KR), Choi; Won-Yun (Seoul, KR), Yoon; Tae-Ki (Seoul, KR)
Assignee:	SUNGKWANG MEDICAL FOUNDATION (Seoul, KR)
Application Number:	14/126,220
Patent Claims:	1. A process of preparing human multipotent stem cells co-expressing CD34 and CD73, comprising: . . . (a) isolating outer surrounding cells of seminiferous tubules from a human testis; (b) culturing the cells isolated in step (a); (c) sorting and isolating cells co-expressing CD34 and CD73 from the cells cultured in step (b) using anti-CD34 and anti-CD73 antibodies; (d) culturing the cells isolated in step (c) up to passage 9 in a medium comprising feeder cells and serum; (e) . . . such that multipotent stem cells co-expressing CD34 and CD73 are obtained; and (f) culturing the multipotent stem cells co-expressing CD34 and CD73 obtained in step (e). 2. The process according to claim 1, wherein the outer surrounding cells of seminiferous tubules are isolated from the human testis using collagenase, dispase, or a mixture thereof. 3. The process according to claim 1, wherein the cells isolated in step (a) are cultured up to passage 4 in culturing of step (b) in a medium comprising feeder cells and serum. 4. The process according to claim 1, wherein the cell-sorting in step (c) and/or step (e) is carried out by magnetic activating-cell sorting. 5. The process according to claim 1, wherein the cells isolated in step (c) is cultured up to passage 7 in step (d) in a medium comprising feeder cells and serum. 6. The process according to claim 1, wherein, the cells isolated in step (e) are cultured up to passage 12 in step (f) in a medium comprising feeder cells and serum. 7. The process according to claim 6, further comprising and isolating the cells cultured in step (f) using an anti-CD34 antibody such that cells co-expressing CD34 and CD73 are obtained, and culturing the isolated cells.

Details for Patent 9,688,961

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965		2031-06-15